Sevoflurane-Remifentanil Versus Propofol- Remifentanil Anesthesia During Noncardiac Surgery for Patients with Coronary Artery Disease - A Prospective Study Between 2016 and 2017 at a Single Center

Dai, Zhongliang1; Lin, Miao1; Li, Yali1; Gao, Wenli1; Wang, Ping1; Lin, Juan1; Wan, Zhenzhen2; Jiang, Yuanxu1

2021-08-21

10.12659/MSM.929835

MEDICAL SCIENCE MONITOR   影响因子和分区

1643-3750

Background: Volatile anesthesia possesses cardioprotective properties, and it is widely used in patients undergoing coro-nary artery bypass surgery, but no randomized controlled trials (RCTs) are available on the use of sevoflurane-remifentanil versus propofol-remifentanil anesthesia for patients with coronary artery disease (CAD) during noncardiac surgery. This study was designed to compare the 2 different types of general anesthesia in patients with CAD undergoing noncardiac surgery at a single center. Material/Methods: Patients with CAD undergoing noncardiac surgery were enrolled in an RCT conducted between March 2016 and December 2017. The participants were randomized to receive either sevoflurane-remifentanil or propofol-remi-fentanil anesthesia. The primary endpoint was occurrence of in-hospital cardiovascular events. The secondary endpoints included delirium, postoperative nausea and vomiting (PONV), Intensive Care Unit (ICU) length of stay (LOS), in-hospital morbidity and mortality, and hospital LOS. Results: A total of 164 participants completed the study (sevoflurane: 81; propofol: 83). The occurrence of in-hospital cardiovascular events did not differ between the 2 groups (42.6% vs 39.4%, P=0.86). The occurrence of delir-ium did not differ between the 2 groups after the operation. PONV had a higher frequency after sevoflurane anesthesia at 48 h compared with propofol. In-hospital morbidity and mortality, ICU LOS, and hospital LOS were similar between the 2 groups (all P>0.05). At 30 days after surgery, no between-group differences in car-diac morbidity and mortality were observed. Conclusions: In this study, anesthesia using sevoflurane-remifentanil did not provide additional postoperative cardioprotec-tion in comparison with propofol-remifentanil in patients with CAD undergoing noncardiac surgery.

Acute Coronary Syndrome Coronary Artery Disease Propofol

SCI

英语

第一 ; 通讯

Shenzhen Municipal Science and Technology Foundation[JCYJ20170307100314152] ; Shenzhen Healthcare Research Project["SZLY2018011","SZXJ2017029"] ; Guangdong Medical Research Fund["A2018008","A2019382"] ; Scientific Research Fund of Shenzhen People's Hospital[SYLY201706]

Research & Experimental Medicine

Medicine, Research & Experimental

WOS:000687833700001

INT SCIENTIFIC INFORMATION, INC

CLINICAL MEDICINE

Web of Science

1.Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2,Affiliated Hosp 1,Dept Anesthesio, Shenzhen, Guangdong, Peoples R China
2.Maternal & Child Hlth Hosp Hubei Prov, Dept Anesthesiol, Wuhan, Hubei, Peoples R China

Dai, Zhongliang,Lin, Miao,Li, Yali,et al. Sevoflurane-Remifentanil Versus Propofol- Remifentanil Anesthesia During Noncardiac Surgery for Patients with Coronary Artery Disease - A Prospective Study Between 2016 and 2017 at a Single Center[J]. MEDICAL SCIENCE MONITOR,2021,27.

Dai, Zhongliang.,Lin, Miao.,Li, Yali.,Gao, Wenli.,Wang, Ping.,...&Jiang, Yuanxu.(2021).Sevoflurane-Remifentanil Versus Propofol- Remifentanil Anesthesia During Noncardiac Surgery for Patients with Coronary Artery Disease - A Prospective Study Between 2016 and 2017 at a Single Center.MEDICAL SCIENCE MONITOR,27.

Dai, Zhongliang,et al."Sevoflurane-Remifentanil Versus Propofol- Remifentanil Anesthesia During Noncardiac Surgery for Patients with Coronary Artery Disease - A Prospective Study Between 2016 and 2017 at a Single Center".MEDICAL SCIENCE MONITOR 27(2021).